Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimenhydrinate is a first-generation antihistamine and anticholinergic agent primarily used for the prevention and treatment of motion sickness, nausea, and vertigo. Chemically, it is a salt consisting of two active components: diphenhydramine (an H1 receptor antagonist) and 8-chlorotheophylline (a chlorinated derivative of theophylline). The drug exerts its therapeutic effects primarily through the diphenhydramine moiety, which competitively inhibits H1 receptors in the vestibular system and the chemoreceptor trigger zone (CTZ) of the brain, thereby reducing vestibular stimulation and nausea. It also possesses significant antimuscarinic properties that contribute to its anti-emetic and sedative effects. The 8-chlorotheophylline component was originally included to mitigate the drowsiness associated with diphenhydramine, although its stimulant effect is relatively weak. Dimenhydrinate is widely available as an over-the-counter medication and is also used in clinical settings for symptomatic relief of peripheral vertigo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimenhydrinate.